Importantly, such therapy does not appear to interfere with anti-tumor immune effector responses (52), raising the possibility that localized therapy directed against the IL-6 axis could counter EMT while unleashing a preexisting, but silenced (8) local anti-tumor response. This evidence concerns the gene IL6 and neoplasm.